GlassScriptPhysician profile
Matthew Kangas
NPI 1750674222
$22,209.91
in general payments reported to CMS, 2019-2025
27 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 75% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,427 · 2020: $1,321 · 2021: $376 · 2022: $1,991 · 2023: $3,566 · 2024: $8,759 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,867 · Travel and Lodging: $5,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,866.88 |
| Travel and Lodging | $5,228.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,726.47 | 2020-2025 | Proclaim, Eterna, Axium |
| Nevro Corp. | $6,723.15 | 2019-2024 | Senza |
| Boston Scientific Corporation | $1,669.53 | 2019-2025 | Intracept |
| Medtronic, INC. | $1,619.42 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Gentleman Orthopedic Solutions | $539.28 | 2020 | |
| Globus Medical, INC. | $331.30 | 2025 | Senza |
| Arthrex, INC. | $318.43 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.78 | 2022-2025 | Relistor |
| Amgen INC. | $253.31 | 2022-2023 | Aimovig |
| Biohaven Pharmaceutical Holding Company LTD. | $244.07 | 2022 | |
| Saluda Medical Americas, INC. | $224.00 | 2025 | Evoke |
| Relievant Medsystems, INC. | $175.28 | 2022-2023 | Intracept |
| Stryker Corporation | $147.17 | 2019-2025 | Mild Device Kit |
| Collegium Pharmaceutical, INC. | $145.50 | 2022-2024 | Belbuca, Xtampza |
| Averitas Pharma INC. | $136.43 | 2024-2025 | Qutenza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $100.00 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Si-Bone, INC. | $94.37 | 2024-2025 | |
| Scilex Pharmaceuticals INC. | $89.07 | 2022-2023 | Ztlido |
| Nalu Medical, INC. | $76.07 | 2023 | Nalu Neurostimulation System |
| Pfizer INC. | $59.83 | 2024-2025 | |
| Abbvie INC. | $51.82 | 2021-2025 | |
| Spr Therapeutics, INC | $51.10 | 2022 | |
| Axsome Therapeutics, INC. | $31.52 | 2025 | Symbravo |
| Lilly USA, LLC | $28.42 | 2022-2023 | Emgality, Reyvow |
| Kowa Pharmaceuticals America, INC. | $24.43 | 2022 | |
| Ibsa Pharma INC. | $22.12 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $18.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kangas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.